ADB-FUBHQUCA

ADB-FUBHQUCA is a synthetic cannabinoid that is also a new psychoactive substance (NPS). It was first identified in Japan in 2019. It is part of a group of substances initially developed in the 1980s and 1990s to investigate the endocannabinoid system.

Chemistry

ADB-FUBHQUCA is a quinolinyl ester analog of FUB-APINACA, which is itself an analog of APINACA. The molecular formula of ADB-FUBHQUCA is C25H25N3O2. It is a white powder in its pure form.

Pharmacology

ADB-FUBHQUCA is believed to act as a potent agonist for the CB1 receptor, which is predominantly located in the central nervous system, and the CB2 receptor, which is primarily found in the peripheral nervous system. However, the exact mechanism of action and pharmacological properties of ADB-FUBHQUCA are not fully understood due to the lack of scientific research.

Effects

The effects of ADB-FUBHQUCA are similar to those of other synthetic cannabinoids and include euphoria, relaxation, altered perception, and adverse effects such as anxiety, paranoia, and psychosis. The potency of ADB-FUBHQUCA is believed to be significantly higher than that of cannabis, which increases the risk of severe adverse effects.

Legal Status

The legal status of ADB-FUBHQUCA varies by country. In many countries, including the United States, United Kingdom, and Japan, it is classified as a controlled substance due to its potential for abuse and the health risks associated with its use.

See Also

• Synthetic cannabinoids
• New psychoactive substances
• Endocannabinoid system
• FUB-APINACA
• APINACA